Formulary Inclusion
When a product is added to the VA National Formulary, it becomes part of the official list of treatments that VA healthcare providers can prescribe. For ActiPatch and RecoveryRx, this means:
They’re recognized as approved therapies within the VA system.
VA clinicians can routinely prescribe them for pain management.
It streamlines access for veterans—no special approvals or workarounds needed.
This is a huge step toward mainstream adoption in federal healthcare.
Direct Reimbursement
Thanks to the NOPAIN for Veterans Act, these devices are now eligible for direct reimbursement by the VA. That means:
Veterans don’t pay out-of-pocket for these therapies.
BIEL receives payment directly from the government for each device used.
It creates a predictable revenue stream for BIEL, especially as usage scales.
This removes a major barrier to adoption and makes the devices more accessible.
VA Prescribing
VA doctors can now prescribe ActiPatch and RecoveryRx just like any other approved treatment. This opens up:
Widespread clinical use across pain management, orthopedics, physical therapy, and post-op recovery.
Integration into prosthetics programs, where RecoveryRx is already being used for residual limb pain.
A pathway for feedback and data collection from real-world use, which can further validate the technology.
The Big Picture
Together, these three milestones mean BIEL’s devices are:
Officially recognized by the VA
Financially supported by federal reimbursement
Clinically accessible to millions of veterans
It’s a trifecta that positions BIEL for explosive growth in the federal healthcare space.
When a product is added to the VA National Formulary, it becomes part of the official list of treatments that VA healthcare providers can prescribe. For ActiPatch and RecoveryRx, this means:
They’re recognized as approved therapies within the VA system.
VA clinicians can routinely prescribe them for pain management.
It streamlines access for veterans—no special approvals or workarounds needed.
This is a huge step toward mainstream adoption in federal healthcare.
Direct Reimbursement
Thanks to the NOPAIN for Veterans Act, these devices are now eligible for direct reimbursement by the VA. That means:
Veterans don’t pay out-of-pocket for these therapies.
BIEL receives payment directly from the government for each device used.
It creates a predictable revenue stream for BIEL, especially as usage scales.
This removes a major barrier to adoption and makes the devices more accessible.
VA Prescribing
VA doctors can now prescribe ActiPatch and RecoveryRx just like any other approved treatment. This opens up:
Widespread clinical use across pain management, orthopedics, physical therapy, and post-op recovery.
Integration into prosthetics programs, where RecoveryRx is already being used for residual limb pain.
A pathway for feedback and data collection from real-world use, which can further validate the technology.
The Big Picture
Together, these three milestones mean BIEL’s devices are:
Officially recognized by the VA
Financially supported by federal reimbursement
Clinically accessible to millions of veterans
It’s a trifecta that positions BIEL for explosive growth in the federal healthcare space.
1
